問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Neurology

更新時間:2023-09-19

楊智超
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

25Cases

2021-05-18 - 2023-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting5Sites

Terminated5Sites

2025-01-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-01-05 - 2029-11-11

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting1Sites

Recruiting8Sites

2024-09-30 - 2026-06-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2017-01-01 - 2018-12-31

Phase IV

A Long-Term, Open-Label, Prospective Observational Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects with End Stage Renal Disease (ESRD) on Dialysis.
  • Condition/Disease

    Hyperphosphatemia/End Stage Renal Disease (ESRD)

  • Test Drug

    NEPHOXIL®

Participate Sites
9Sites

Terminated9Sites

2011-06-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2008-01-01 - 2008-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2013-12-01 - 2018-01-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2016-04-01 - 2023-06-30

Phase III

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran
  • Condition/Disease

    ATTR patients with symptomatic polyneuropathy (FAP)

  • Test Drug

    Patisiran

Participate Sites
2Sites

Terminated2Sites

2018-01-31 - 2022-12-31

Phase III

ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias
  • Condition/Disease

    Acute Hepatic Porphyrias (AHP)

  • Test Drug

    Givosiran (ALN-AS1)

Participate Sites
3Sites

Terminated3Sites

1 2 3